Publication | Closed Access

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission

InflammationTherapeutic Drug MonitoringAnti-inflammatoryClinical RemissionImmunologyGastroenterologyDrug MonitoringPharmacotherapyInfliximab TherapyUlcerative ColitisMedicineRheumatoid Arthritis